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Small molecule cytokine mimetics 
Adrian Whitty and Christopher W Borysenko 
A number of reports describe small peptides, and even bona 
fide small organic molecules, that activate homodimeric 
cytokine receptors and show cytokine-like activity in vitro and 
in viva. These cases can be examined in light of the 
mechanistic and thermodynamic principles that govern 
cytokine-receptor activation. 
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Introduction 
Cytokines are extracellular signaling molecules that 
mediate communication between cells and their envi- 
ronment through interaction with cell-surface receptors 
[1,2]. Members of this extensive family of proteins play 
key roles in many critical biological processes includ- 
ing regulation of the cellular and humoral immune 
responses. hematopoiesis, inflammation, wound healing 
and apoptosis. Given the varied and important biologi- 
cal activities of cytokines. it is not surprising that many 
successful protein drugs are either cytokines them- 
selves, or antibodies or soluble receptor mimics that 
antagonize cytokine function. Examples of cytokines that 
are marketed as drugs include human growth hormone 
(hGH), erythropoietin (EPO), granulocyte colony-stimu- 
lating factor (G-CSF), granulocyte-macrophage colony- 
stimulating factor, interferon-a, interferon-p, interleukin 
(II,)-2 and IL-1 1. Numerous other cytokines or cytokine- 
receptor antagonists are in advanced stages of clinical 
development. All of these protein drugs share the key 
drawback that they must be delivered to the patient per- 
enterally, for example by subcutaneous, intramuscular or 
intravenous injection. There is therefore great interest in 
developing cytokine agonists or antagonists that are 
orally available. One approach to achieving this aim 
involves developing small-molecule agonists that can 
activate cytokine receptors, or small-molecule antago- 
nists that block the response to a cytokine by interacting 
with its receptor or with downstream components of its 
signaling pathways. Until recently, there was reason to 
believe that the task of finding a small-molecule agonist 
that could mimic the action of a protein the size of a 
typical cytokine (-15-50 kDa) would be extremely diffi- 
cult, if not impossible. Recent reports have shown, 
however, that relatively small peptides [3-S]. and even 
hona fide small organic molecules [6,7]. can bind to and 
activate certain homodimeric cytokine receptors, and 
can, to some degree, mimic the effects of these cytokines 
in vitro and in a& in experimental systems. Here we 
examine these cases in light of the mechanistic and ther- 
modynamic principles that govern cytokine-receptor 
activation. In so doing, we discuss the essential proper- 
ties of small molecule cytokine-receptor agonists, and we 
examine various strategies for identifying and optimizing 
lead molecules. Although examples from the literature 
include only agonists of homodimeric crtokine recep- 
tors (i.e. those receptors comprising two identical recep- 
tor chains), we include a brief discussion of how the 
lessons learned from these published examples might 
apply to receptors of more complex stoichiometry. and 
also to receptor antagonists. 
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Receptor activation by ligand-induced receptor 
chain dimerization 
For a number of cytokines, receptor activation has been 
shown to occur by a mechanism of l&and-induced receptor 
chain oligomerization [&lo]. This mechanism can be 
exemplified by the human growth hormone receptor 
(GH-R) [l 11, a class I cytokine receptor [l]. GH-R com- 
prises two identical subunits, each of which is a single-pass 
transmembrane protein containing an extracellular portion 
comprising two fibronectin type-III repeats, a membrane- 
spanning region and a cytoplasmic portion of unknown 
structure. The receptor is activated via a two-step mecha- 
nism, as shown in Figure 1 [IZ]. In the first step, hGH (L) 
binds to the extracellular portion of one receptor chain (R) 
to form a binary complex, R-L. Subsequently, a second 
GH-R molecule binds to form a ternary complex, R*L*R. 
Recruitment of the second GH-R chain is brought about 
by the combination of existing weak binding sites in GH-R 
and hGH into a single, extended binding site in R.1, that 
confers significantly increased affinity for binding the 
second GH-R chain [ 111. The net effect of hGH binding to 
the cell is therefore to bring two molecules of GH-R 
together into a single complex, such that signaling kinases 
that are noncovalently associated with the cytoplasmic por- 
tions of the receptor chains can interact with each other 
and with additional downstream signaling molecules, thus 
transmitting the signal to the interior of the cell. A signifi- 
cant body” of data supports the notion that, for GH-R 
[11,12], and several other homodimeric class I cytokine 
receptors such as the receptors for EPO (EPO-R) [13,14], 
G-CSF (G-CSF-R) [l&15] and thrombopoietin (TPO-R) 
[16-181, the bringing together of two receptor chains on 
the cell surface is necessary to trigger signaling (see the 
note at end of the text for a recently proposed alternative 
mechanism for EPO-R activation). Important details such 
as the role of conformational changes in the receptor 
[19,20], the precise orientation between receptor chains 
required for signaling [21,22], the involvement of higher- 
order receptor aggregation events subsequent to formation 
of the initial ternary complex [23,24], and the importance 
of on- and off-rate kinetics [ZS] are still being determined, 
however. In addition to the homodimeric class I receptors 
mentioned above, a mechanism of ligand-induced receptor 
dimerization has been established or is strongly indicated 
for a number of other oiigomeric cytokine receptors, 
including the heterodimeric receptor for IL-4 comprising 
the IL-4Rcr and common gamma (r,) chains [26.27], the 
heterotrimeric receptor for IL-Z [28], and the tetrameric 
(a,$,) receptor for IFN-y [29]. Moreover, analogous activa- 
tion mechanisms have also been established for a number 
of oligomeric receptors of other structural classes such as 
TNF family members [9], and tyrosine kinase and 
serine/threonine kinase receptors for growth factors such as 
EGF and TGF-b [8,30]. As a result, it has become widely 
assumed that most or all of the receptors that fall into any 
of the structural classes represented in the examples above 
Figure 1 
r 
I  
w w 
KI K2 
V 
JANUS kinase 
Chemistry & Bmlog 
The ligand-induced receptor dimerization mechanism as it applies to a 
homodimeric class I cytokine receptor such as GH-R (adapted from 
191). Receptor activation occurs in two steps. The cytokine or agonist 
ligand (L) binds to one receptor chain (R), with dissociation constant 
K,, to form binary complexes, R-L. In a subsequent step, R-L recruits 
a second receptor chain to form a ternary complex, R*L-R. The affinity 
of this second step, which is a bimolecular association event 
constrained to the two dimensions of the cell membrane, is given by 
the dissociation constant K,, which has units of molecules/urn2 [27]. 
The bringing together of the receptor cytoplasmic domains, together 
with their associated JANUS signaling kinases, allows them to interact 
with each other and with additional downstream signaling molecules, 
thereby transmitting the signal to the interior of the cell. At very high 
concentrations of L, the system is forced into a state in which all R 
molecules are occupied by an equivalent number of L molecules, 
therefore antagonizing the formation of receptor dimers, as illustrated 
by the lower pathway. Note that the extent of direct contact between 
the receptor chains in R-L*R varies for different receptors, and that the 
agonist ligand can have either identical or nonidentical binding sites 
for the receptor. 
are activated by ligand-induced oligomerization [ 10,301, 
although some exceptions or significant mechanistic varia- 
tions might exist even among closely related members of 
the cytokine receptor superfamily [31,32]. 
The task confronting small-molecule agonists 
of cytokine receptors 
To trigger the activation of a receptor such as GH-R by 
directly cross-linking two receptor chains, as illustrated in 
Figure 1, an agonist ligand must achieve the following: it 
must bind to one of the receptor chains with reasonable 
affinity; it must do so in a position such that additional 
unsatisfied binding functionality projects in the direction 
required for contact with a second receptor chain; it must 
have a sufficient affinity for the second receptor chain to 
shift the equilibrium for receptor dimerization to signifi- 
cantly favor the dimeric state of the receptor; the resulting 
receptor dimers must have a relative orientation between 
receptor chains that leads to productive interaction 
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between the receptor cytoplasmic domains and their asso- 
ciated signaling molecules; and it might also be important 
that the activating ligand has a sufficiently slow dissocia- 
tion rate such that the lifetime of the activated receptor 
complexes exceeds the threshold required for effective 
signaling to occur. Examination of published cases of 
peptide or small molecule cytokine-receptor agonists 
allows us to assess the degree to which each of these 
requirements was successfully met in different cases, and 
therefore to draw inferences about the relative importance 
of these different properties for the function of a small- 
molecule receptor agonist. 
Published examples of peptide and small 
molecule cytokine-receptor agonists 
Peptide or small-molecule agonists have been reported for 
three different cytokine receptors: EPO-R, TPO-R and 
G-CSF-R. All three are homodimeric receptors from the 
class I subfamily of cytokine receptors [l]. In 1996, 
Wrighton et a/. [3] reported the discovery of a 20 residue 
cyclic peptide, EMP-I (Figure Za), derived from phage 
selection, that competes with EPO for binding to a soluble 
form of the EPO-R extracellular domain and, at micro- 
molar concentrations, stimulated cell proliferation in an 
EPO-dependent functional assay. Phosphotyrosine analy- 
sis of the lysates of stimulated cells suggested that EMP-1 
and EPO induced the phosphorylation of a similar set of 
intracellular proteins, and that they had similar effects on 
cell-cycle kinetics. EMP-1 also showed activity in viva in 
two murine models of erythropoiesis. A crystal structure of 
the complex of EMP-1 with recombinant soluble EPO-R 
showed that the complex contains two EMP-1 molecules 
in contact with two receptor molecules [33], indicating that 
EMP-1 functions as a homodimer. This conclusion was 
substantiated by reports that covalently coupling EMP-1 
molecules to enforce a dimeric structure enhanced agonist 
activity by greater than tenfold [34]. Structure-activity 
studies of EMP-1 have led to the construction of a yet 
smaller derivative peptide, a 13-mer called IMP-20 
(Figure Zb), that in cell proliferation assays in vitro has 
agonist activity roughly comparable to EMP-1 [3.5]. The 
same group responsible for EMP-1 has also reported a 
covalently dimerized 1Cresidue peptide, AF13948 
(Figure Zc), again derived from a phage-selection approach, 
that was able to activate a different homodimeric cytokine 
receptor, TPO-R, in assays measuring TPO-R-dependent 
cell proliferation, megakaryocyte colony formation and 
magakaryocyte maturation in vitro [4]. Remarkably, this 
peptide appeared virtually equipotent with recombinant 
human TPO in these assays. The authors also report that 
AF13948 was active in a mouse model of thrombopoiesis. 
A second group [S] has subsequently reported the inde- 
pendent discovery of phage-derived peptide TPO-R ago- 
nists of related sequence to those of Cwirla et al. [4], and 
have demonstrated that one of them activates JAK/STAT 
signaling in a TPO-responsive cell line [36]. 
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Structures of some reported examples of peptide and small molecule 
cytokine-receptor agonists. (a) EMP-1 [3]; (b) EMP-20 [35]; 
(c) AF13946 141; (d) SB247464 [6]; (e) TM41 [71. (a) and (b) bind to 
EPO-R as noncovalent dimers; (c) comprises two identical 14-mer 
peptides covalently dimerized by means of a lysine-b-alanine linker. 
Reports of small organic molecules that possess cytokine 
receptor agonist activity also exist. Tian eta/. [6] described 
a small organic molecule, SB247464 (Figure Zd), that at 
micromolar concentrations showed agonist activity 
towards the murine G-CSF-R. This molecule (molecular 
weight -500 Da), was derived by screening a compound 
library directly for agonist activity in a cell-based assay 
using a muG-CSF-dependent reporter gene. SB247464 
also gave responses in several other muG-CSF-dependent 
colony-forming and signaling assays-including demon- 
strating an ability to induce G-CSF-dependent signaling 
events such as the phosphorylation of G-CSF-R itself, 
JAKl, JAK3, STAT3 and STATS-and showed activity 
in VZVO in a murine model of granulopoiesis [6,37]. 
SB247464 appeared highly specific: it did not elicit a 
response in assays dependent on activation of the recep- 
tors for EPO, interferon-a or interferon-y and, strikingly. 
was also unable to activate the human G-CSF-R in similar 
types of in vitro assays. More recently, Kimura et al. [7] 
have reported a small organic molecule, TM41 
(Figure Ze), that competes against TPO in a TPO-R- 
binding ELISA, and, at a concentration of -100 @I, was 
shown to stimulate cell proliferation and to activate 
STATS in a human TPO-R-dependent cell line [7]. 
Agonist potency and efficacy and bell-shaped 
dose-response curves 
A striking characteristic of the small-molecule G-CSF-R 
agonist SBZ47464 was that it gave bell-shaped dose- 
response curves in a variety of cell-based functional assays 
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Dependence of the concentration of the activated receptor complex 
R-L-R (expressed as a fraction of total receptor, [RI,) on the 
concentration of cytokine or agonist ligand, L. The curves shown were 
calculated from the equations of Perelson and DeLisi [36] for a value of 
[R],/K, = 100. (a) The agonist concentration that produces the maximal 
level of R-L-R and therefore defines the mid-point of the bell-shaped 
curve is equivalent to K,, the dissociation constant for the initially formed 
binary complex R-L (see Figure 1). The ligand concentration resulting in 
half-maximal R*L*R is designated EC,, and the ligand concentration 
resulting in 50% self-inhibition of R-L-R formation is similarly designated 
IC,,. The width of the curve at half-maximal height is given by IC,,/ECs,, 
and defines the effective dose range (EDR) over which the agonist ligand 
will produce at least half-maximal R*L*R formation, The EDR is a function 
of the effective affinity for the binding of R.L to R to form R-L-R, which 
depends on K, (Figure 1) and on [R]T, the total concentration of receptor 
present locally on the cell surface. The amplitude of the curve at [L] = K, 
is shown by the blue line (short dashes). The theoretical maximum 
amplitude of [R-L-R] = 1/2[R], is shown by the green line (long dashes). 
(b) Identical simulation to that shown in (a), but showing how each of the 
three forms of the receptor, [R*L*R] (solid line), [R-L] (short dashes) and 
[R] (long dashes), varies with the concentration of agonist ligand. 
[6,37]. Peak response was observed at -1 pM SBZ47464, 
independent of the assay used. The concentration of 
SB247464 required for peak activity was several logs 
higher than that required for the natural murine cytokine, 
which, in the same assays. achieved a maximal response at 
-10-100 pM. Moreover, in some assays the amplitude of 
the signaling response seen at peak doses of SB247464 
was several-fold lower than the response seen with muC- 
CSF itself. Efficient optimization of the properties of a 
molecule such as SB247464 clearly requires an under- 
standing of how the dose-response curve observed in 
functional assays can be quantitatively related to the inter- 
actions between the molecule and the target receptor. 
Bell-shaped dose-response curves in cell-based functional 
assays are a characteristic feature of homodimeric receptors 
that are activated by ligand-induced dimerization [l&14]. 
Because the two receptor chains involved in the signaling 
complex are identical, at very high concentrations of ligand 
the system becomes forced into a state in which each 
receptor molecule is occupied by a separate molecule of 
ligand (Figure l), such that, at equilibrium, virtually all 
receptor molecules are present as R-L complexes. There 
is, therefore, little formation of the ternary R0L.R complex 
- and hence little receptor activation - at either very low 
or very high concentrations of agonist ligand (Figure 3), 
and functional assays that depend upon the formation of 
R*L*R complexes show self-antagonism by the ligand at 
high concentrations. Such behavior is expected in homod- 
imeric receptors systems, whether the receptor is activated 
by a small molecule such as SB247464, by monoclonal anti- 
bodies targeted to the receptor extracellular domains 
[l&14,17] or by the natural cytokine itself [12,14,2.5], when 
dimerization is induced by the binding of a single agonist 
molecule. Other, related activation mechanisms can also 
give bell-shaped dose-response curves (see below, and 
note at end of text). Experimental observation of a full 
bell-shaped dose-response curve is sometimes difficult, 
however, if self-antagonism occurs only at very high con- 
centrations of the agonist ligand, as is typically true for 
highly potent agonists [ 141. 
Importantly, a mathematical treatment applicable to the 
ligand-induced dimerization mechanism has been 
described by Perelson and DeLisi [38], resulting in equa- 
tions that can be used to calculate how the concentration 
of R*L.R varies as a function of the concentration of L. 
The published equations can be applied directly to sym- 
metrical agonists, and the discussion that follows is framed 
in these terms. Application of the equations to asymmetri- 
cal agonist such as hGH itself strictly speaking requires 
statistical correction by a factor of two, but the effect of 
this correction on the behavior of the systems we discuss 
here is negligible. Receptor activation and signaling is a 
direct consequence of the formation of R*L*R complexes, 
so this treatment provides a basis for interpreting experi- 
mental dose-response data from functional assays in terms 
of the separate interaction affinities of the agonist ligand 
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with each of the two receptor chains (i.e. in terms of K, 
and K, from Figure 1). In cell-based experimental 
systems, the application of these mathematical treatments 
is complicated by the fact that the dependence of the 
functional response on R*L*R formation might not be 
linear. For example, in the case of so-called ‘spare recep- 
tors’ [l&39] the receptor is present in excess with respect 
to one or more limiting downstream signaling compo- 
nents, and therefore a maximal response is achieved with 
activation of only a fraction of the available receptors. For- 
tunately, such nonlinearity does not preclude the applica- 
tion of this model to functional data to allow meaningful 
and quantitative conclusions to be drawn about the 
binding properties of the agonist ligand. A detailed discus- 
sion of the mathematical treatments themselves is beyond 
the scope of this article, but conclusions derived from 
their application to agonists of homodimeric cytokine 
receptors [ 14,393 are summarized below. 
Significance of the mid-point of the dose-response curve 
Assuming cytotoxicity effects and other assay artifacts can 
be excluded. the equations of Perelson and DeLisi [3X] 
predict that the concentration of agonist ligand that corre- 
sponds to the peak or mid-point of the bell-shaped 
dose-response curve should equal K,, the affinity of the 
ligand for binding to the first receptor chain (Figure 1). 
Figure 1 shows that the initial binding of L to R and the 
self-antagonism that occurs at very high concentrations of 
L are both governed by K, (Figure l), so at [L] = K, these 
effects are equally balanced and the concentration of 
R*L*R is maximal (Figure 3) [38]. A nonlinear relationship 
between the concentration of R*L*R and the size of the 
functional response, such as would be seen with spare 
receptors, would be expected to have an equal effect on 
the agonist and antagonist limbs of the dose-response 
curve, and would therefore be expected to preserve sym- 
metry about K, (391. In a cell-based functional assay a 
bell-shaped dose-response curve that is centered around a 
hgand concentration of 1 @I therefore implies that L 
binds to the first receptor chain with K,, = 1 /.LLM 
(Figures 3,4a). This interpretation can potentially be con- 
firmed by independent experiments because direct deter- 
mination of the affinity of this interaction is sometimes 
possible [ 141. 
Significance of the width of the dose-response curve 
In a functional assay in which a given agonist shows a bell- 
shaped dose-response, the ratio of the IC,, for self-antago- 
nism to the EC,, for the agonist response represents the 
width of the dose-response curve at half its maximum 
height (Figure 3). This ratio can be thought of as a measure 
of the effective dose range (EDR) for the agonist in the 
assay concerned, because it equals the range of concentra- 
tions over which the agonist gives a half-maximal or greater 
response. It can be inferred from application of Perelson 
and DeLisi’s equations [38] that the magnitude of the 
Figure 4 
i (a) 0.6 
I- o,3- 
1% 
0.2. 
0.1 
0.0 
-----.- _I-_-- 
0.01 K, 
1 i’ ‘I’ 
Log [agonist ligand] 
I :b) o’61 
1 
i 
Log [agonist ligand] 
Chemstry &Blology 
How the bell-shaped dose-response curve for R-L-R formation as a 
function of agonist ligand concentration varies with changing values for 
K, or K,. The curves shown were calculated using the mathematical 
treatment of Perelson and DeLisi [38]. The theoretical maximum 
amplitude of [R-L-R] = 1 /2[RIT is shown by the green line (long 
dashes). (a) For fixed values of K, and [RIT, increasing or decreasing 
K, by a factor of 100 causes the mid-point of the dose-response 
curve to shift to correspondingly higher or lower agonist 
concentrations. The width and amplitude of the curve are unaffected. 
(b) For fixed values of K, and [RIT, decreasing K, by incremental 
factors of 10 over the range of values [R],/K, = 0.1-l 0,000 increases 
the width and amplitude of the dose-response curve without altering 
its mid-point. A decrease in the dissociation constant K, corresponds 
to an increase in the affinity of R-L for binding to R on the cell surface 
(Figure 1). An identical result would be obtained if [RI, were increased 
at constant K,. The theoretical minimum width of IC,,/EC,o = 30 is 
shown by the vertical dotted lines. 
EDR will be governed primarily by the effective affinity of 
the second step in receptor activation, that is the local or 
effective affinity of R-L for binding to R on the cell 
surface. This effective affinity is governed by K,, the 
intrinsic affinity for the binding of R to R*L (Figure l), but 
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depends also on the local density of receptor chains present 
on the cell membrane [27]. A high intrinsic affinity (i.e. a 
low KZ) and a high local concentration of receptor chains on 
the cell surface both favor the observation of a wide 
dose-response curve (Figure 4b). This is because the more 
thermodynamically stable is R-L-R, the lower is the con- 
centration of L required to form R*L*R, and the higher - 
by an identical factor - the concentration of L required to 
disrupt R*L*R formation through the self-antagonism illus- 
trated in Figure 1. The experimental observation of a very 
broad dose-response curve would therefore indicate that 
the total concentration of receptor on the cell surface ([R17-) 
is much larger than K,, and therefore the effective affinity 
for the binding of R-L to R on the cell surface is high. (For 
a discussion of the dimensionality issues inherent in this 
comparison, arising from the need to consider receptor con- 
centration in the two dimensions of the cell membrane, see 
[27].) The relationship between [R*L*R] and [Rll./Kz that 
underlies this expected effect on the width of an experi- 
mental dose-response curve is illustrated in Figure 4b. The 
sensitivity of EDR to variations in K, has been shown 
experimentally by means of mutations in the region of the 
cytokine involved in binding the second receptor chain 
[ 121. Published data showing bell-shaped dose-response 
curves for cytokines such as EPO [14] and hGH [12,25,39] 
in cell-based assays show EDR values of up to 6 logs, sug- 
gesting that there is a high effective affinity of R*L for R on 
the cell surface in these cases [27]. In addition to the above- 
mentioned parameters, the width of the dose-response 
curve in a functional assay is also influenced by factors that 
affect the quantitative relationship between the extent of 
receptor activation (i.e. the level of R*L*R formation) and 
the functional response. The existence of spare receptors, 
for example, would in some circumstances be expected to 
somewhat broaden the dose-response curve [ 12,391. 
Significance of the amplitude of the dose-response curve 
The level of functional response achieved at the peak of a 
bell-shaped dose-response curve, as compared with the 
maximal response that would be expected for 100% recep- 
tor activation, is another measure of how effective the 
agonist is at inducing the formation of R*L=R complexes. 
Applying the equations of Perelson and DeLisi [38] leads 
to the prediction that this measure is also primarily gov- 
erned by the total receptor concentration on the cell 
surface and by K,. Only if [R17. is high relative to K, will 
the effective affinity for the binding of R*L to R be suffi- 
cient to induce the majority of receptors to become dimer- 
ized, even at the peak of the dose-response curve. For 
example, to bring about dimerization of -80% of receptor 
molecules at [L] = K,, [R],,/K, must be = 80 [38]. Even in 
the case of a very strong association between R-L and R, a 
low response or no response might be observed if the 
geometry of the resulting R-L-R complex does not allow 
the receptor chains to achieve a relative orientation that is 
suitable for efficient signaling [21,22]. A clue to diagnosing 
this situation can be gained from the shape of the 
dose-response curve. For example, if EDR is large (i.e. 
greater than -3 logs), a maximal signal that is significantly 
lower than that seen for the natural cytokine in the same 
assay is unlikely to be due to a low effective affinity of R*L 
for R, because the width of the dose-response curve 
implies that at [L] = K, the majority of R chains exist as 
R-L-R complexes. Such an observation would instead tend 
to suggest that the agonist ligand is effective at promoting 
dimerization of the receptor, but that the resulting 
complex has a geometry that is not optimal for signaling. 
A recent report by Pearce el al. [ZS] suggests that predic- 
tions such as those made above, derived from an equilib- 
rium model, might break down for highly potent agonists 
for which kinetic effects have become dominant. Whether 
such observations will prove to be a general characteristic of 
receptor systems of this kind represents an exciting new 
line of inquiry. Their conclusions support the notion that 
the equilibrium mode1 is applicable to agonist ligands that 
have only weak or moderate potency, however. It therefore 
seems likely that the conclusions drawn from analysis of the 
equilibrium model can fruitfully be applied to the discovery 
and characterization of small-molecule lead compounds that 
have agonist activity, and to the optimization of these prop- 
erties at least up to the point where they begin to approach 
the activity seen for the natural cytokines. 
Analysis of reported peptide and small molecule cytokine- 
receptor agonists 
The fact that the small-molecule muG-CSF-R agonist 
SB247464 gave bell-shaped dose-response curves in 
several cell-based functional assays, taken together with 
the molecule’s twofold rotational symmetry (Figure 2d) 
and the known ability of dimerized G-CSF-R to signal [12], 
strongly suggests that SB247464 brings about activation of 
the receptor by forming a 1:2 complex with G-CSF-R 
(although this might not be true for G-CSF itself, for which 
various stoichiometries in addition to 1:2 have been pro- 
posed for the complex [40]). Evaluating the published 
dose-response curves for SB247464 in the light of the 
above analysis allows us to draw a number of inferences 
about the interactions of the agonist with the two G-CSF-R 
molecules presumed to exist in the activated receptor 
complex. The fact that the peak response is consistently 
seen at an agonist concentration of - 1 PM SB247464 across 
several different functional assays [6,37] implies that the 
molecule binds to the first receptor chain with an affinity of 
K, = 1 @I. The amplitude of the dose-response curve 
obtained with SB247464 in a muG-CSF-R-dependent 
luciferase promoter assay is relatively low; the peak 
response for the small molecule is only -30% of the 
maximal response seen with muG-CSF in the same assay. 
The dose-response curve was also shown in several assays 
to be narrow, with IC,j,,/EC,,= 30, which is close to the 
theoretical lower limit (Figure 4b). These two features 
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imply that the binding of SBZ47464 to one molecule of 
G-CSF-R results in the induction of only a relatively low 
effective affinity for the binding of a second G-CSF-R mol- 
ecule at the receptor expression level that exists on the cells 
used. The relatively low peak signaling amplitude implies 
that, even at [SB247464] = K,, only a fraction (albeit a sub- 
stantial one) of receptors become dimerized on these cells. 
The fact that the amplitude of the dose-response curve 
appears approximately commensurate with its narrow width 
implies, however, that the R*L*R complexes that form 
bring the receptor chains into a mutual orientation that 
leads to relatively efficient signaling. Although increasing 
the efficacy and potency of SB247464 presumably would 
require modification of its structure to increase its affinity 
for G-CSF-R and thereby lower K, and K?, it appears that 
this molecule provides a good framework for structural 
embellishment and optimization to achieve this result. 
The EPO-R agonist EMP-1 (Figure 2a) forms a 22 
complex with the receptor, and therefore does not 
conform to the mechanistic paradigm ihustrated in 
Figure 1. The two molecules of EMP-1 make direct 
contact with each other in the receptor complex, and the 
binding energy derived from this interaction is presum- 
ably almost wholly responsible for stabilizing the dimer- 
ized form of the receptor as the area of direct contact 
between receptor chains is relatively small [33]. Func- 
tional assays that require formation of a 2:2 complex and 
involve significant productive contact between ligand 
molecules would also be expected to give rise to a bell- 
shaped dose-response curve, because a high enough con- 
centration of EMP-1 would be expected to force the 
system into a state in which all receptor chains are individ- 
ually occupied by noncovalent EMP-1 dimers, resulting in 
the predominance of a nondimerized R*L*L state by a 
pathway analogous to the lower pathway in Figure 1. The 
experimental data reported for Eh,IP-1 [3] do not extend 
to high enough concentrations of EMP-1 to unambigu- 
ously establish this expected self-antagonist behavior. In 
contrast, covalently dimerized derivatives of EMP-1 pre- 
sumably form a 1:2 complex with EPO-R, and therefore 
would be expected to follow the mechanism shown in 
Figure 1 and to manifest the behavior described in 
Figures 3 and 4. Indeed, a biotinylated form of EMP-1, 
when cross-linked through streptavidin, does appear to 
give a bell-shaped dose-response in proliferation assays 
and, additionally, displays enhanced potency [34]. Other 
covalently dimerized forms of EMP-1 show EC,” values 
that are more than tenfold lower than that found for EMP- 
1 itself [34]. The dose-response data reported for these 
covalently dimerized forms is not sufficient to establish 
definitively the expected bell-shaped dose-response, but 
the data shown suggest that EDR is 2 3 logs in a prolifera- 
tion assay based on cells made EPO-dependent by trans- 
fection with EPO-R. Even this lower limit suggests that 
the binding of dimeric forms of EMP-1 to EPO-R induces 
a substantial effective affinity for EPO-R dimerization at 
the level of receptor expression present on the cells used. 
It is difficult to draw any conclusions about how either the 
width or the amplitude of the dose-response curve for 
EMP-1 and derivatives compares with that seen for EPO 
itself because the reports do not show a side-by-side com- 
parison of these agonists in the same experiment, but in a 
different assay EPO has been shown to have an EDR of 
-6 logs [14]. (See note at end of text.) 
The TPO-R agonist peptide of Cwirla et al. [4], AF13948, 
is also a covalent dimer of identical peptide sequences 
(Figure 2~). On the basis of the >lOOO-fold enhanced 
potency of AF13948 compared with the monomeric 
peptide from which it was derived [4] and the known 
ability of dimerized TPO-R to signal [ 17,181, AF13948 can 
also be presumed to form a 1:2 complex with its receptor. 
As was the case for EMP-1, published dose-response data 
for AF13948 also do not extend to high enough agonist 
concentrations to fully define the expected self-antagonis- 
tic portion of the dose-response curve, although it is possi- 
ble to set a lower limit of EDR of 2 2 logs for the peptide 
(and for TPO itself) in a proliferation assay based on 
TPO-R-transfected Ba/F3 cells. A direct comparison with 
the natural cytokine [4] indicates that AF13938 achieves a 
functional response with an amplitude and an EC,, that 
were indistinguishable from that of TPO. This result does 
not necessarily imply that AF13948 dimerizes TPO-R as 
effectively as does TPO. In the absence of fully defined 
dose-response curves we cannot be sure. for example. that 
the peptide does not induce dimerization with a higher K, 
that is being offset by a lower value for K,. Nevertheless, 
the dimerization achieved by AF13948 is clearly sufficient 
to achieve a level of R*L*R complexes that can effectively 
match the response seen with the cytokine in this assay. 
Finally, data for the small-molecule TPO-R agonist of 
Kimura et al. [7], TM41 (Figure 2e), show hints of a bell- 
shaped dose-response, but the data are not sufficient to 
clearly define the mid-point or the width of the curve 
beyond the lower limits of K, 2 100 pM and EDR 2 30. 
One conclusion that can be drawn from examination of the 
EPO-R and TPO-R studies cited above is that, despite the 
extensive and highly informative characterization to which 
the agonist molecules were subjected, detailed analysis of 
the binding energetics that underlie their ability to bring 
about receptor activation is. in most cases, hampered by a 
failure to fully define the expected self-antagonistic limb of 
the functional dose-response curves. Although fully defm- 
ing the predicted bell-shaped dose-response curve might 
be superfluous to the characterization of a particular agonist 
when considered in isolation, the unique information that 
such data can provide could be critical for any meaningful 
comparison of the properties of different agonists for the 
same receptor, and as such might play an important role in 
optimizing the properties of such molecules. 
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Lessons for screening and lead optimization 
The reports described above exemplify several different 
approaches to identifying lead molecules with agonist 
properties towards homodimeric cytokine receptors. The 
G-CSF-R agonist SBZ47464 was discovered by directly 
screening a compound library for agonist activity, using a 
G-CSF-R-dependent reporter gene assay [6]. In contrast, 
Wrighton et a/. [3] working with EPO-R, and Cwirla et al. 
[4] and Kimura et al. [j] working with TPO-R used phage 
display technology to screen for peptide sequences that 
bound to the extracellular region of the receptor, and then 
tested for agonist activity in a secondary assay. Wrighton et 
al. [3] benefited from the unexpected ability of a peptide 
to bind to the receptor as a dimer, whereas Cwirla et ai. [4] 
covalently dimerized their molecule as a deliberate strat- 
egy. The success of dimerizing a molecule identified 
through its ability to bind to a single receptor chain, to 
convert it into a molecule that can induce the dimerization 
of two receptor chains, might be highly sensitive to the 
shape, size and conformational preferences of the linker 
structure [21,22]. It is likely, therefore, that even the early 
stages of agonist lead discovery will benefit from testing a 
range or library of dimer constructs in which the linker is 
varied to allow a range of distances and orientations 
between the binding moieties to be tested. 
Some specific suggestions regarding lead discovery can 
be drawn from consideration of the published cases cited 
above. 
Choice of compound dilutions for use in agonist screening 
assays 
Even in the best cases, initial lead molecules are likely to 
be relatively weak agonists with low effective dose ranges. 
Screening compounds directly in an agonist-activity assay 
at a single high concentration might therefore result in 
active compounds being overlooked, because the poten- 
tial for self-antagonism could cause a compound that is 
active at lower concentrations to appear inactive at higher 
ones. The theoretical minimum value for the effective 
dose range can be calculated from the mathematical 
model of Perelson and DeLisi [38], and has a value of 
IC,dEC,, - 30 (Figure 4b). Testing compounds ocer as 
wide a concentration range as possible using 30-fold serial 
dilutions should therefore ensure that at least one test 
concentration falls between the putative agonist’s EC,, 
and its IC,,, giving a response that is at least half of the 
peak response. Screening test compounds using fivefold 
serial dilutions would be expected to give at least two data 
points with >.50% maximal agonist response, which might 
help identify both false positive and false negative results. 
Assays based on high-expressing cell lines 
As mentioned above, the effective dose range for an 
agonist is predicted to be a function of K2 and of the con- 
centration of receptor chains expressed on the cell surface 
(Figures 3 and 4b), and can also be influenced by the level 
of spare receptors. The relationship illustrated in 
Figure 4b suggests that cell-based assays used to screen 
directly for agonist activity are likely to be more sensitive 
in their detection of weak agonists if the target receptor is 
expressed at high levels, provided that ligand-indepen- 
dent signaling remains negligible. The relative sensitivi- 
ties of different candidate cell lines can be assessed by 
comparing the effective dose ranges found using the 
natural cytokine or, if the full bell-shaped dose-response 
cannot practically be determined with the cytokine itself, 
by choosing cell lines that give the lowest EC,,, for stimu- 
lation with the cytokine (Figure 4b). An additional conse- 
quence of this sensitivity to receptor expression levels is 
that, because both the extent of any spare receptors and 
the density of receptor expression on the cell surface 
might vary from day to day, the same agonist might give 
dose-response curves of varying widths in different assa>is. 
Unless such variations can be excluded or controlled, it is 
prudent to ensure that quantitative comparisons of the 
properties of different agonist molecules are performed 
only with data obtained in the same experiment. 
Lead optimization: deconvoluting agonist structure-activity 
data 
The information provided by a quantitative analysis of 
dose-response data can be extremely valuable to the lead 
optimization process, whether using traditional methods, 
sophisticated structure-based strategies or a combinatorial 
chemistry approach. This is because only such an analysis 
can provide a quantitative picture of how the previous 
round of structural changes affected the affinity of the com- 
pounds for binding to each of the two receptor chains in the 
R*L*R complex. A key question. therefore. is how this 
information can be extracted from the kind of bell-shaped 
dose-response curves seen for lead molecules such as 
SB247464. The quantitative analysis of bell-shaped 
dose-response curves described above suggests that 
7 
changes In the ECS,, values observed for the agonist 
responses of a set of molecules does not necessarily corre- 
late with changes in their binding affinity to one or the 
other receptor chain. For example, a structural modification 
to a lead molecule might increase the molecule’s affinity for 
binding to the first receptor chain (i.e. decrease K,), but if 
the modification resulted in a poorer geometry for bridging 
across to the second receptor chain, it might significantly 
decrease dimerization efficiency by raising K2. The net 
effect of these changes would be to shift the dose-response 
curve to the left but also to narrow it and, depending on the 
balance between these effects, the EC,, value might 
increase, decrease or stay the same. An experimental 
example of such a case is referred to by Dower [41]. Clearly, 
in order to understand the consequences for activity of 
structural changes in the agonist, it is necessary to consider 
their effects on K, and KZ separately. For a system exempli- 
fying the behavior described above, this aim can be 
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Figure 5 
How the effects of changes in the properties of the agonist ligand can 
potentially be deconvoluted, thereby allowing a quantitative analysis of 
the changes in terms of their effects on K, and K,, by considering 
separately variations in the mid-point of the curve and in IC,,/EC,,. The 
left-hand column shows simulated dose-response data, generated using 
the equation of Perelson and DeLisi [38] assuming that response is 
proportional to [R-L-RI. The right-hand column shows the result of 
plotting the mid-point versus ICs,-JEC,, for each compound, illustrating 
how the effect of any particular structural change can potentially be 
quantified. The color of each data point in the right-hand plots matches 
that of the corresponding simulated dose-response curve shown in the 
left-hand column. (a) The predicted effects for a series of compounds in 
which the affinity for binding to each of the two receptor chains IS 
changing proportionately, such as might be seen as a consequence of 
symmetrical modifications being made to both of the identical receptor- 
binding regions of a covalently dimerized or symmetrical agonist. A set of 
compounds of this type would be expected to result in dose-response 
curves that show correlated changes in width and mid-point, as 
illustrated by the simulated data shown. The plot of mid-point versus 
IC,,/EC,, illustrates the deconvolution of the dose-response cures to 
highlight and quantify the underlying proportionate changes in K, and K,. 
The black curve, and its corresponding data point that falls below the line 
in the plot of mid-point versus IC,,/EC,,, represents a compound with a 
K, value that is disproportionately lower than K,, such as might result 
from a structural change that reduced the ability of a relatively tight 
binding agonist to bridge between the receptor chains. (b) Predicted 
effects for a series of compounds with identical affinities for bindmg to 
the first receptor chain, but varying abilities to promote dimerization of 
the receptor (i.e. compounds that show variations in K, but not K,). 
A pattern such as this might be seen for a set of covalently dimerized 
agonist compounds containing identical ligand-binding regions 
connected through linker structures of varying geometry. A set of 
compounds of this type would be expected to cause the dose-response 
curve to change in width and amplitude but to cause little or no change 
in the mid-point, as illustrated by the simulated data shown. The plot of 
mid-point versus IC,,/EC,, illustrates how the underlying effects on K, 
can potentially be quantified. (c) Predicted effects for a series of 
compounds with varied properties, as shown by the simulated data. The 
plot of mid-point versus IC,,IECs, illustrates how the effect of any 
specific structural change can be determined in terms of whether, and by 
how much, it affected K,, K, or both. The dotted lines illustrate how 
relationships between the activities of subsets of compounds that share 
certain binding properties can be identified and quantified In this way. 
achieved by considering separately the effects of structural 
changes on the mid-point of the dose-response curve (i.e. 
effects on K,), and on the effective dose range (i.e. on 
IC,,jECj,, which is a measure of K,), and using these 
effects as separate indices of binding to the first and second 
receptor chains, respectively. This suggestion presupposes 
that a full bell-shaped dose-response curve (i.e. data suffi- 
cient to define both ECj,, and IC&) can be obtained for 
each compound included in the analysis. as was done for 
SB247464 [6]. An illustration of how such an analysis might 
be utilized is shown in Figure 5, which shows three sets of 
simulated dose-response curves, such as might be expected 
to arise from assaying sets of test compounds designed 
using three different lead optimization strategies, and 
attempts to illustrate how effects on K, and K, can be 
deconvoluted and quantitatively analyzed. A limitation to 
this approach is that, for very weak agonists (e.g. those with 
IC,dEC,, < 100). the width of the dose-response curve is 
Log [test compound] 
Log [test compound] 
I 
Log [test compound] Log(IC,,IEC,,) 
predicted to become relatively insensitive to changes in 
K, [38]. Nevertheless, the simulations in Figure 5 suggest 
that analyzing dose-response data in terms of the changes 
in mid-point and in IC+$EC,, might constitute a useful 
approach to deconvoluting and interpreting agonist dose- 
response data. 
Agonists versus antagonists 
In addition to the utility of orally available cytokine-recep- 
tor agonists, there is also considerable scope for the thera- 
peutic application of receptor antagonists. hlany of the 
lessons inferred from the quantitative analysis of receptor 
activation, described above, can be equally well applied to 
developing molecules designed to prevent activation from 
occurring. For example, it was stated above that molecules 
that bind to the receptor but confer insufficient affinity for 
binding a second receptor chain make poor agonists. Such 
molecules are promising starting points for antagonist 
development, however, because they bind to and occupy 
the receptor but do not induce dimerization and activation 
efficiently. How such a lead molecule might behave is 
illustrated by the black curve in Figure 5a. One target 
profile for an antagonist would therefore be to aim for a 
molecule that has a low K, value and a high K, value; that 
is a molecule with a high affinity for binding to the first 
receptor chain but negligible propensity to cause receptor 
dimerization. If  such a molecule binds in a site that blocks 
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binding of the natural cytokine, it will act as an antagonist. 
Proteinaceous molecules with these properties have been 
obtained by site-directed mutagenesis of cytokines [ 121. It 
must be noted, however, that a number of cytokine recep- 
tors have been extensively screened for inhibitors using a 
variety of conventional approaches, and this activity has 
not generally led to the discovery of potent small-mole- 
cule antagonists. This anecdotal evidence implies that, 
even for cytokine-receptor pairs that derive most of their 
interaction affinity from localized binding ‘hotspots’ [ 111, 
it is not a trivial undertaking to identify a small molecule 
that binds to one receptor chain with sufficient affinity to 
directly block cytokine binding. 
Two alternative approaches to targeting such receptors can 
therefore be considered. The first involves setting up the 
screening assay to specifically target the second step in 
receptor activation, the binding of R*L to R (Figure 1). In 
certain cases, this second step in receptor activation might 
be of lower affinity - and therefore easier to block - than 
the initial binding of the cytokine to R [27]. The analysis 
presented above suggests that screening assay formats and 
conditions can potentially be chosen that, in contrast to a 
typical competitive binding ELISA, allow or even favor the 
discovery of molecules that block the dimerization step. 
For example, by screening in a functional assay for mole- 
cules that can inhibit the activity of a very high concentra- 
tion of cytokine, the assay might thereby be biased against 
the detection of molecules that block the initial binding of 
cytokine to R - a step in direct competition with cytokine 
binding - and biased towards the detection of molecules 
that inhibit by alternative means, such as by blocking 
dimerization. Alternatively, antagonists that block dimer- 
ization could, potentially, be detected using a ceil-based 
receptor-binding competition assay in which the concen- 
tration of labeled cytokine competitor is fixed at around 
EC,, and is well below K,. Under these conditions, signifi- 
cant binding of the labeled cytokine will be seen only if 
the second receptor chain is able to participate in the for- 
mation of a ternary complex, so molecules that block 
receptor dimerization will be detected as inhibitors of 
cytokine binding in this assay. A second alternative 
approach to developing antagonists involves aiming for 
molecules that, like agonists, can bind two receptor chains 
simultaneously. Instead of optimizing the linker element 
of a dimeric lead molecule to aim for a productive orienta- 
tion of receptor chains, however, such a molecule might be 
optimized for a nonproductive alignment that does not 
result in signaling. The potential advantage of this 
approach is that the inhibitor gains the avidity advantage of 
binding to two receptors simultaneously, and therefore 
enjoys the enhanced binding affinity that can be achieved 
by combining two moderate-affinity interactions to give 
high-affinity binding. This approach is likely to be 
restricted to receptors that have fairly stringent require- 
ments for receptor chain orientation, however. 
Cytokine receptors of more complex 
stoichiometry 
Homodimeric receptors, such as GH-R, EPO-R, G-CSF-R 
and TPO-R, comprise only a small subset of the broad 
family of cytokine receptors [ 1,301. It is therefore useful to 
consider how the ideas discussed above might apply to 
cytokine receptors of more complex stoichiometry or 
mechanism. A group of receptors that are closely related in 
structure and mechanism to the homodimeric receptors 
discussed above are class 1 cytokine receptors of hetero- 
dimeric composition [l]. Viewed in functional terms, this 
group can be considered to include any class I cytokine 
receptor that is activated by the ligand-induced association 
of two dissimilar receptor subunits. These can be formally 
heterodimeric receptors, such as the receptor for IL-4 
comprising the IL-4Ra and yc chains [26,27]. but can also 
include certain receptors of higher formal stoichiometry, 
such as the IL-Z receptor that comprises the IL-ZRa, IL- 
2Rp and “I, receptor chains [B]. The IL-2Ra and IL-ZRP 
chains are pre-associated on the cell surface [42], and the 
key step in the activation of this receptor is therefore the 
bimolecular association of the preformed IL-Za/p complex 
with yc; this receptor, and perhaps other formally het- 
erotrimeric receptors such as IL-lSR, can therefore be 
considered as functionally heterodimeric. The develop- 
ment of small-molecule agonists or antagonists of het- 
erodimeric receptors that are activated by l&and-induced 
dimerization is highly analogous to the homodimeric cases 
discussed above, except for considerations of symmetry. 
Instead of identifying a molecule that can bind to one R 
chain and then duplicating it as a covalent dimer, an analo- 
gous approach for heterodimeric receptor targets would be 
to screen or select for molecules that bind to each of the 
receptor chains separately, and then link the selected and 
presumably dissimilar lead fragments together via an 
appropriate linker or scaffold. An alternative approach 
would involve screening for molecules that bind tightly to 
one receptor chain, and then using the resulting binding 
fragments as the basis for a more open-ended combinator- 
ial library that can be screened in a functional assay to 
identify derivatives able to engage in simultaneous 
binding to the second receptor chain. The development of 
antagonists of heterodimeric cytokine receptors, and par- 
ticularly the potential for achieving inhibitors that act non- 
competitively with respect to the cytokine, has been 
discussed elsewhere [27]. In addition to these het- 
erodimeric systems, lessons learned from peptide and 
small-molecule agonists of homodimeric class I cytokine 
receptors are likely to apply equally to other classes of 
receptor that are activated by a mechanism of ligand- 
induced receptor-chain oligomerization [30]. 
Conclusions 
A number of peptides and small molecules have been 
described that have activity as agonists of homodimeric 
cytokine receptors. We have discussed these cases in terms 
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of the thermodynamic and mechanistic principles underly- 
ing the receptor-activation mechanism of ligand-induced 
dimerization. Moreover, we have attempted to show that 
this kind of analysis can allow the properties of these mole- 
cules to be understood in terms of the requirements for 
binding to and appropriately orienting two receptor chains 
to bring about activation and signaling. The results suggest 
a number of ways in which strategies for lead discovery and 
lead optimization can be evaluated. In particular, we 
promote the value of obtaining experimental dose- 
response data that fully define both limbs of the bell- 
shaped curve expected for agonists of homodimeric recep- 
tors in cell-based functional assays. We also advocate 
approaching the analysis of structure-activity data from 
such assays by considering the effects on the mid-point 
and on the width of the dose-response curves as separate 
indices of the affinity of the agonist molecule for binding 
to the first and second receptor chains, respectively. 
Preconceptions about whether or not a certain goal can be 
achieved can be pivotal in determining whether or not it is 
in fact accomplished; such beliefs have an even greater 
impact on defining what is attempted. Thanks to the excit- 
ing recent reports on peptide and small-molecule agonists 
of cytokine receptors reviewed here, practitioners of small- 
molecule drug discovery have now been given reason to 
believe that small molecules might be developed that have 
the essential functional properties of much larger proteina- 
ceous cytokines. In so doing, these paradigm-shifting results 
might have brought the possibility of orally available drugs 
with cytokine-like activity a large step closer to reality. 
Note added in proof 
Since this article was submitted, two reports have been published 
which suggest that EPO-R might exist as preassociated, inactive 
dimers in the absence of EPO (Livnah, O., Stura, E.A., Middleton, S.A., 
Johnson, D.L., Joliffe, L.K. & Wilson, I.A. (1999). Science 283, 987- 
990; Remy, Y., Wilson, LA. & Michnick, S.W. (1999). Science 283, 
990-993). The authors of these studies propose that binding of EPO 
activates the receptor by bringing about a particular orientation 
between receptor chains within the pre-existing dimer. If this proposal 
is correct, other published data concerning activation of EPO-R place 
significant restrictions on how such a mechanism might function. For 
example, the observation of self-antagonism by EPO (141 implies that, 
at very high concentrations of EPO, the preassociated receptor dimers 
can be converted to an inactive (EPO),(EPO-R), complex analogous 
to the lower pathway in Figure 1, Derivation of the appropriate binding 
equations (C.W.B. & A.W., unpublished observations) demonstrates 
that, in the simplest case consistent with these restrictions, a preasso- 
ciated receptor mechanism of this kind might result in behavior essen- 
tially identical to that described in Figures 3 and 4, with the exception 
that the width of the bell-shaped dose-response curve would be 
expected to be insensitive to the receptor expression level. 
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